Can-Fite BioPharma Ltd. (CANF), Friday announced that the Brazilian Patent Office has granted patent entitled Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.
Following this, the granted patent provides intellectual-property protection in Brazil for the use of Can-Fites proprietary A3AR agonists in the treatment of sexual dysfunction.
The patent reflects the company's broader clinical and preclinical programs, which is expected to help create future partnering or commercialization opportunities in Latin America.
In the pre-market hours, CANF is trading at $0.24, down 1.94 percent on the New York Stock Exchange American.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.